더바이오 11월 3일 주요뉴스
https://www.thebionews.net/edit/webzine.html?idxno=675
● 셀트리온·삼성에피스, ‘키트루다’ 무효심판 다른 셈법…핵심은 9개월 ‘우판권’
https://www.thebionews.net/news/articleView.html?idxno=29758
● 임델트라·파드셉 병용 연이어 성공한 ‘임핀지’…알테오젠, SC 플랫폼 ‘활짝’
https://www.thebionews.net/news/articleView.html?idxno=29759
● 中·獨 ‘바이오시밀러’ 동맹…최대 37종 개발 협력에 삼성·셀트리온 경쟁 가열
https://www.thebionews.net/news/articleView.html?idxno=29762
● 中 허치메드, MET 증폭 폐암에 ‘오파티스·타그리소’ 병용 유럽·日 허가 신청
https://www.thebionews.net/news/articleView.html?idxno=29761
● [컨콜] 사노피, 아델 ‘ADEL-Y01’ 협력 유지…SK바사 ‘GBP410’ 결과 눈앞
https://www.thebionews.net/news/articleView.html?idxno=29785
● 美, ‘세포유전자치료제 품질관리 지침’ 15년만에 개정…전 주기 품질관리 강화
https://www.thebionews.net/news/articleView.html?idxno=29786
● LG화학, 美 리듬과 희귀 비만신약 기술수출 규모 확대…총 1조1500억원
https://www.thebionews.net/news/articleView.html?idxno=29783
● 퍼스트바이오, 100억원 규모 투자 유치 완료…“SK바이오팜도 SI로 참여”
https://www.thebionews.net/news/articleView.html?idxno=29776
● “임상시험서도 ‘종이문서 시대’ 저문다…AI 전환 준비해야”
https://www.thebionews.net/news/articleView.html?idxno=29792
● 디앤디파마텍, 간섬유화 신약 후보 내년 1상 진입…“경구 펩타이드 개발 확대”
https://www.thebionews.net/news/articleView.html?idxno=29790
● 애브비·中 브리즈, 1조원 규모 ‘편두통’ 신약 협력 진전…초기 마일스톤 달성
https://www.thebionews.net/news/articleView.html?idxno=29787
● 유니큐어, ‘AMT-130’ 헌팅턴병 유전자치료제 美 우선심사…내년 5월 결론
https://www.thebionews.net/news/articleView.html?idxno=29788
● 알테오젠, 분기 매출 첫 1000억원 돌파…영업익 789억원 ‘역대 최대’
https://www.thebionews.net/news/articleView.html?idxno=29784
● GC녹십자, ‘국민성장펀드’ 1700억원 자금 조달 승인…‘20% SCIG’ 개발 속도
https://www.thebionews.net/news/articleView.html?idxno=29770
● 삼성바이오로직스, 글로벌 제약사와 4343억원 규모 위탁생산 계약
https://www.thebionews.net/news/articleView.html?idxno=29767
● 스카이랩스, 보령과 AI 의료 데이터 플랫폼 연계…우주의학 진출
https://www.thebionews.net/news/articleView.html?idxno=29769
● 베르티스, 지씨셀과 SURF 기반 신규 타깃 발굴·세포치료제 개발
https://www.thebionews.net/news/articleView.html?idxno=29778
● 팬젠, ‘바이오유럽’ 참가…“EPO 의약품 유럽 시장 정조준”
https://www.thebionews.net/news/articleView.html?idxno=29781
● 파마리서치, 주요 산부인과 학술대회 참가…‘자이너’ 학술 교류 확대
https://www.thebionews.net/news/articleView.html?idxno=29780
● 갤럭스, 신용보증기금 ‘Pre-ICON’ 선정…최대 70억원 보증 지원 확보
https://www.thebionews.net/news/articleView.html?idxno=29774
● Aprilbio takes part in ‘BIO Europe’ – “Actively pursuing strategic collaboration with global partners”
https://www.thebionews.net/news/articleView.html?idxno=29804
● D&D Pharmatech takes over key pipeline from U.S. Subsidiary ‘Neuraly’ – “Strengthening business control”
https://www.thebionews.net/news/articleView.html?idxno=29803
● QVIS sharpens focus on Japan's clinical quality control and pharmacovigilance market, discussing cooperation strategies with 52 companies
https://www.thebionews.net/news/articleView.html?idxno=29796
● PanGen Biotech Participates in 'Bio Europe 2026', Targeting the European Market with EPO Biosimilar
https://www.thebionews.net/news/articleView.html?idxno=29801
● GI Innovation and TriOar co-develop next-generation masking multispecific antibodies
https://www.thebionews.net/news/articleView.html?idxno=29800
● Inventage Lab secures Phase 1 CSR for 1-month continuous drug addiction treatment, strengthening L/O foundation
https://www.thebionews.net/news/articleView.html?idxno=29799
● RudaCure inks development and technology transfer deal with France's Ceva for new canine dry eye treatment
https://www.thebionews.net/news/articleView.html?idxno=29798
● Bukwang Pharmaceutical teams up with Samsung Medical Center and BlueSignum to develop digital therapeutic for schizophrenia
https://www.thebionews.net/news/articleView.html?idxno=29797
● Samsung Medical Center and Israel’s Alpha Tau Medical sign MOU to launch exchange and cooperation in pancreatic cancer
https://www.thebionews.net/news/articleView.html?idxno=29795
● IMGT: “Ultrasound boosts pancreatic cancer drug delivery – Heads into U.S. confirmatory clinical trials, eyes KOSDAQ”
https://www.thebionews.net/news/articleView.html?idxno=29794
*제약바이오 11월 3일 아침 유튜브 라디오 뉴스(매일 아침 업로드)
https://www.youtube.com/watch?v=WoVpXjI8E5Q